Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathwaysSherif Ibrahim, Martin Götte|Molecular Cancer|2017Cited by 276
Syndecan-1 (CD138) Modulates Triple-Negative Breast Cancer Stem Cell Properties via Regulation of LRP-6 and IL-6-Mediated STAT3 SignalingSherif Ibrahim, Martin Götte|PLoS ONE|2013Cited by 117
Small extracellular vesicle-encapsulated miR-181b-5p, miR-222-3p and let-7a-5p: Next generation plasma biopsy-based diagnostic biomarkers for inflammatory breast cancerSarah Hamdy Ahmed, Sherif Ibrahim|PLoS ONE|2021Cited by 42